Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | PTPRB | P23467 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16101520 | 0.89 | OPRD1 (0.48) | JAK2JAK1OPRD1OPRK1TSHR | |
| SCHEMBL5523771 | 0.86 | JAK2 (0.48) | JAK2JAK1OPRD1OPRK1TSHR | |
| SCHEMBL13277303 | 0.84 | OPRD1 (0.45) | JAK2JAK1OPRD1OPRK1TSHR | |
| SCHEMBL8649196 | 0.84 | OPRD1 (0.45) | JAK2JAK1OPRD1OPRK1TSHR | |
| SCHEMBL27655696 | 0.84 | NAMPT (0.43) | OPRD1OPRK1KDM4EACHE | |
| SCHEMBL27313194 | 0.83 | OPRD1 (0.47) | JAK2JAK1OPRD1OPRK1TSHR | |
| SCHEMBL12492182 | 0.83 | OPRD1 (0.43) | JAK2JAK1OPRD1OPRK1TSHR | |
| SCHEMBL2951728 | 0.83 | OPRD1 (0.53) | OPRD1OPRK1TSHRALOX15TACR1 | |
| SCHEMBL12493077 | 0.81 | ATM (0.45) | JAK2JAK1OPRD1OPRK1TSHR | |
| SCHEMBL22834092 | 0.81 | OPRD1 (0.51) | OPRD1OPRK1TSHRALOX15TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241770-B2 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7241770-B2 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7241770-B2 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| EP-1694675-A2 | HYDRONOPOL DERIVATIVES AS AGONISTS ON HUMAN ORLI RECEPTORS | Solvay Pharmaceuticals GmbH (DE) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058890-A2 | HYDRONOPOL DERIVATIVES AS AGONISTS ON HUMAN ORL1 RECEPTORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131004-A1 | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARMACEUTICALS GMBH. | 2005-06-16 | — | — | US | disclosed |
| US-20050059658-A1 | Pyridazinone | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059658-A1 | Pyridazinone | TYMP, TPMT, PDXK | JAK2 2719/4885JAK1 1925/4885OPRD1 4406/4885 |
| US-20050131004-A1 | Hydronopol derivatives as agonists on human ORL1 receptors | OPRL1, ORMDL3, OGFRL1 | JAK2 1509/4885JAK1 2164/4885OPRD1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.